THE EFFECT OF GENETIC POLYMORPHISMS ON EX VIVO PLATELET AGGREGATION

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 血小板功能障碍是动脉粥样硬化的重要病理因素（1）。改变血小板功能的药物，如雌激素，可能会改变患者发生冠状动脉疾病的风险。遗传变异也决定了血小板对许多药物的反应。调节血小板功能的基因中的单核苷酸多态性（SNP）可能有助于对药物反应的个体间差异。我们已经建立了一个离体血小板聚集协议，研究药物对血小板聚集的影响。本研究的目的是使用基因分型前的血小板，以评估当血小板暴露于药物时，遗传多样性对离体血小板聚集的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Platelet dysfunction is an important pathological contributor to atherosclerosis (1). Medications, such as estrogens that change platelet function may alter the risk of developing coronary artery disease in patients. Genetic variants also determine platelet response to many medications. Single nucleotide polymorphisms (SNPs) in genes that regulate platelet function may contribute to this inter-individual variation in response to medications. We have established an ex vivo platelet aggregation protocol to study the effect of medications on platelet aggregation. The goal of this study is to use pre-genotyped platelets to evaluate the effect of genetic diversity on the ex vivo platelet aggregation when the platelets are exposed to medications.